Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, upadacitinib and filgotinib, are
increasingly used in the treatment of rheumatoid arthritis (RA). There has been debate about …

Background Atherogenic index of plasma (AIP) represents a novel marker in the current era
of cardiovascular diseases. In this meta-analysis, we aimed to evaluate the association of …

Objective To examine the joint associations between physical activity and abdominal obesity
with the risk of cardiovascular disease (CVD) events. Methods We included 70 830 UK …

Background Patients with peripheral artery disease are at increased risk for major adverse
cardiac events, major adverse limb events, and all‐cause death. Developing tools capable …

Introduction Chronic kidney disease (CKD) causes a progressive loss of muscle and bone
mass, which frequently overlap with and affect clinical outcomes. However, the impact of …

Importance Evolving evidence suggests that patients receiving Janus kinase–signal
transducer and activator of transcription inhibitors (JAK-STATi) may be at higher risk of major …

Methods We retrospectively analyzed 4,124 treatment-naïve CHB patients treated with TDF
(n= 3,186) or TAF (n= 938) between 2012 and 2022. The primary outcome was a composite …

Background Lean metabolic dysfunction-associated steatotic liver disease (MASLD),
characterized by a BMI< 25 kg/m² (or< 23 kg/m² in Asians), presents a challenging prognosis …

Importance Hypertension affects 6% of all children, and its prevalence is increasing.
Childhood hypertension tracks into adulthood and is associated with subclinical …

Cardiovascular diseases (CVD) are common in long COVID, yet the associated risk remains
uncertain. We aimed to quantify the risk of new‐onset cardiovascular diseases after COVID …